Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blau FarmaceuticaBSP:BLAU3 -0.77%87 Gross Margin % is 41.44% as of Mar. 2026, which is 5% below its 10-year median of 43.63. GuruFocus rates BSP:BLAU3 with a GF Score™ of 87/100 and a GF Value™ of R$11.17 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 941 Drug Manufacturers companies, Blau Farmaceutica ranks worse than 64.51% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Blau Farmaceutica had a gross margin of 41.44% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Blau Farmaceutica Gross Margin % Related Terms
Blau Farmaceutica Gross Margin % Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:BLAU3 vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Blau Farmaceutica (BSP:BLAU3) has a Gross Margin % of 41.44% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Blau Farmaceutica and its competitors. This is near median its historical median of 43.63. Over the past decade, Blau Farmaceutica's Gross Margin % has ranged from 35.72 to 48.74. According to the industry distribution chart, Blau Farmaceutica ranks #607 out of 941 companies in the Drug Manufacturers industry, placing it in the top 64.5%.
Is Blau Farmaceutica's Gross Margin % too high?
Blau Farmaceutica's current Gross Margin % of 41.44% is near median its 10-year median of 43.63. Over the past 10 years, this metric has ranged from a low of 35.72 to a high of 48.74. The Drug Manufacturers industry median Gross Margin % is 48.54. Blau Farmaceutica's value of 41.44% is 14.6% below this industry median. Based on the distribution chart, Blau Farmaceutica ranks #607 out of 941 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Blau Farmaceutica has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #607 out of 941 companies for Gross Margin %. This places Blau Farmaceutica in the lower half of its industry. The industry median Gross Margin % is 48.54. Blau Farmaceutica's value of 41.44% is 14.6% below this benchmark. Historically, Blau Farmaceutica's own Gross Margin % has ranged from 35.72 to 48.74 over the past decade. While the company's 10-year median is 43.63 vs. the industry median of 48.54, Blau Farmaceutica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blau Farmaceutica's current Gross Margin % of 41.44% is 14.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current Gross Margin % is 41.44%, which is near median its own 10-year median of 43.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$11.17, compared to a current price of R$8.98 — trading 19.6% below its estimated fair value. The current Gross Margin % is 41.44%, which is near median its 10-year median of 43.63 and 14.6% below the Drug Manufacturers industry median of 48.54. Blau Farmaceutica's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current Gross Margin % is 41.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$8.98 is trading 19.6% below its estimated GF Value™ of R$11.17.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
Gross Margin %: 41.44% (near median its 10-year median of 43.63)
GF Value™: R$11.17 vs. price of R$8.98 (19.6% below fair value)
Industry Position: 14.6% below the Drug Manufacturers median (#607 of 941)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
87GF Score
Get the complete analysis for BSP:BLAU3
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
